Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and immunogenicity of an inactivated varicella-zoster vaccine in adults with hematologic malignancies receiving anti-CD20 therap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Inactivated Varicella Zoster Virus Vaccine (Varicella Zoster Virus vaccine (inactivated))

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Herpes Zoster | Phase 1 | Status: COMPLETED | Results posted: 2019-03-11